Overview

• An Oval Office announcement is expected Friday, with a White House official telling MSNBC that AstraZeneca will adopt a most‑favored‑nation model and sell discounted medicines via TrumpRx.gov, alongside a reported $50 billion U.S. investment.
• Pfizer previously agreed to offer many primary‑care and select specialty drugs at roughly 50% off on TrumpRx, set new drugs at MFN levels, and extend MFN pricing to Medicaid in exchange for a three‑year tariff reprieve tied to U.S. manufacturing.
• GoodRx and major pharmacy groups say they are in discussions to participate and are pressing for manufacturer discounts to be usable at retail counters so patients do not have to navigate separate direct‑sale channels.
• Experts caution that many direct‑to‑consumer programs are cash‑pay and may not accept insurance or count toward deductibles, meaning uninsured or underinsured patients could benefit more than those with robust coverage, and Medicaid savings may accrue mainly to government budgets.
• The administration says the site will launch in 2026 and is courting additional drugmakers, though key details such as which drugs will be included, how prices will be set, and whether insurance will be integrated remain undisclosed.